Previous Close | 134.42 |
Open | 134.38 |
Bid | 132.37 x 800 |
Ask | 170.00 x 1000 |
Day's Range | 130.99 - 134.38 |
52 Week Range | 78.00 - 286.19 |
Volume | 132,563 |
Avg. Volume | 604,896 |
Market Cap | 3.871B |
Beta (5Y Monthly) | 1.66 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
SAN FRANCISCO, April 10, 2021 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today announced that it will host a conference call to discuss the recent publication by Novitas Solutions (“Novitas”) of rates applicable to the Current Procedural Terminology (CPT) codes 93243 and 93247. On April 10, 2021, Novitas published updated reimbursement rates for codes 93243 and 93247 at $103 and $115, respectively. The updated rates are retroactive to January 1, 2021 and replace rates initially published on January 29, 2021. iRhythm is assessing the impact of the updated Novitas rates on its business and will provide comments on a conference call on April 12, 2021. Webcast and Conference Call InformationiRhythm will host a conference call on April 12, 2021 at 5:30 AM PT / 8:30 AM ET to provide commentary on the newly published rates by Novitas. Investors interested in listening to the conference call may do so by accessing the live and archived webcast of the event available on the “Investors” section of the company’s website at: www.irhythmtech.com. About iRhythm Technologies, Inc. iRhythm is a leading digital health care company redefining the way cardiac arrhythmias are clinically diagnosed. The company combines wearable biosensor devices worn for up to 14 days and cloud-based data analytics with powerful proprietary algorithms that distill data from millions of heartbeats into clinically actionable information. The company believes improvements in arrhythmia detection and characterization have the potential to change clinical management of patients. Investor Relations ContactLeigh Salvo(415) 937-5404investors@irhythmtech.comMedia ContactMorgan Mathis310-528-6306irhythm@highwirepr.com
NEW YORK, NY / ACCESSWIRE / April 2, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court.
Los Angeles, California--(Newsfile Corp. - April 2, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against iRhythm Technologies, Inc. ("iRhythm" or "the Company") (NASDAQ: IRTC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between August 4, 2020 and January 28, 2021, ...